CEP
BPMC

Chicago Equity Partners’s Blueprint Medicines BPMC Stock Holding History

Chicago Equity Partners’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-4,495
Closed -$360K – 676
2019
Q4 		$360K Sell
4,495
-4,015
-47% -$301K 0.02% 711
2019
Q3 		$625K Buy
+8,510
New +$736K 0.03% 628

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Chicago Equity Partners's BPMC Position: Q1 2020 in Review

Chicago Equity Partners sold out of Blueprint Medicines (BPMC) in Q1 2020, closing a stake of 4,495 shares — an estimated $360K sold.

Chicago Equity Partners first reported a position in BPMC in Q3 2019 and held it in 2 quarters. The position peaked at $625K in Q3 2019. 213 funds tracked by Wall St. Rank hold BPMC as of Q1 2020.

  • Chicago Equity Partners reported no remaining Blueprint Medicines position as of Q1 2020 after selling out during the quarter.
  • Chicago Equity Partners sold 4,495 Blueprint Medicines shares in Q1 2020, an estimated $360K.
  • Chicago Equity Partners first reported a position in Blueprint Medicines in Q3 2019 and held it in 2 quarters.
  • Chicago Equity Partners's Blueprint Medicines position peaked at $625K in Q3 2019.
  • 213 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2020.

Based on Chicago Equity Partners's 13F filing for Q1 2020, filed 6 May 2020.